To include your compound in the COVID-19 Resource Center, submit it here.

One amyloid candidate left for Biogen, Eisai after axing BACE trials

Despite ending two Phase III trials of BACE inhibitor elenbecestat Friday, Biogen and Eisai have not walked away from the amyloid hypothesis of Alzheimer’s disease. The partners' Phase III trial of anti-amyloid mAb BAN2401 forges on, treating about 1,600 more patients with an amyloid agent.

Biogen Inc. (NASDAQ:BIIB) and Eisai Co.

Read the full 516 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE